NEW YORK (360Dx) – iBio said today it and Oneway Diagnostica of Brazil have reached a deal to develop point-of-care diagnostic tests for Brazil with an initial focus on Zika and chikungunya.
As part of the deal, iBio will provide antigen and antibody manufacturing for product prototype development, regulatory approval, commercial launch, and ongoing commercialization efforts, while Oneway will manage marketing, distribution, and sales in Brazil.
The initial phase of the collaboration has started and is being conducted by iBio scientists at the its subsidiary iBio CDMO in Texas and Oneway medical and scientific advisors in Brazil. The partners have agreed to use iBio's technologies for the production in plants of recombinant antigen proteins and antibodies selected to enable the manufacturing and distribution of diagnostic products in Brazil.
iBio will receive service fees and "participate in sales revenues," it said. No additional terms of the agreement were disclosed.
iBio develops plant-based biopharmaceuticals. Oneway is a division of Veloz Importadora e Distribuidora and provides POC and immunoassay kits for in vitro diagnostics and ELISA and real-time PCR tests.